US 11,787,867 B2
Anti-GITR antibodies and uses thereof
Robert Babb, River Edge, NJ (US); Drew Dudgeon, Montvale, NJ (US); Yu Huang, Ossining, NY (US); Rosalynn Molden, Shoreline, WA (US); William Olson, Yorktown Heights, NY (US); Matthew Sleeman, Yorktown Heights, NY (US); Dimitris Skokos, New York, NY (US); and Bei Wang, Hastings-on-Hudson, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Mar. 5, 2021, as Appl. No. 17/193,586.
Claims priority of provisional application 62/986,494, filed on Mar. 6, 2020.
Prior Publication US 2021/0340267 A1, Nov. 4, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01)] 24 Claims
OG exemplary drawing
 
1. An isolated antibody or antigen-binding fragment thereof that binds glucocorticoid-induced tumor necrosis factor receptor (GITR), wherein
the antibody or antigen-binding fragment thereof comprises: (i) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:4, the HCDR2 comprises the amino acid sequence of SEQ ID NO:6, and the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:36, and SEQ ID NO:42; and (ii) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:12, the LCDR2 comprises the amino acid sequence of SEQ ID NO:14, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:16.